Fusafungin

Fusafungin is an antibiotic obtained from the fungus Fusarium lateritium (WR strain 437) or other Fusarium species and used against infections of the upper respiratory tract .

Information on fusafungin
Wikidata	Fusafungin (Q222424)
CAS number	1393-87-9
EC number	215-737-5
ECHA ID	100.014.306
PubChem	308409
DrugBank	DB08965
ATC code	R02 AB03

properties

From a chemical point of view, this is an ionophoric peptide antibiotic that is a mixture of enniatin A, B, C and possibly other components. Enniatins are cyclic depsipeptides in whose ring-shaped backbone the peptide bond R – CO – NH – R ' alternates three times with the ester bond R – CO – O – R' ( cyclohexadepsipeptides , CHDPs ).

Fusafungin is a solid that melts at 125-129 ° C. It is almost insoluble in water, but soluble in glycols and fats .

Effect and application

Fusafungin is effective against various gram-positive and gram-negative germs as well as Candida albicans . It has a bacteriostatic and bacteriocidal effect . It also has its own anti-inflammatory component.

Fusafungin was applied locally ( topically ) in the form of metered sprays ( aerosols ).

Revocation of admission

Due to an increasing number of severe allergic reactions, especially bronchospasm , and possible development of resistance which recommended Pharmacovigilance Committee for Risk Assessment (Pharmacovigilance Risk Assessment Committee, PRAC) of the European Medicines Agency in February 2016 revoking fusafungine-containing approvals. As a result, the Federal Institute for Drugs and Medical Devices (BfArM) revoked all approvals of pharmaceuticals containing fusafung in Germany with effect from May 28, 2016 with a step-by-step decision of May 2, 2016.

Trade names

Monopreparations

Locabiosol (D, A), Locabiotal (CH), Bioparox (CZ)

literature

S. Firáková, B. Proksa, M. Sturdíkova: Biosynthesis and biological activity of enniatins . In: Die Pharmazie 62 (8) (2007), pp. 563-568. PMID 17867547
D. Levy, A. Bluzat, M. Seigneuret, JL Rigaud: Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins . In: Biochemical Pharmacology 50 (12) (1995), pp. 2105-2107. PMID 8849339
H. Masson: A new antibiotic: fusafungine in the field of otorhinolaryngology . In: Revue de laryngologie - otologie - rhinologie 75 (1–2) (1954), pp. 51–58. (in French) PMID 13156249
MeSH: Fusafungine

Individual evidence

↑ HPT Ammon (Ed.): Hunnius Pharmaceutical Dictionary . 9th edition. Walter de Gruyter, Berlin a. New York 2004, p. 617.
↑ European Committee for Risk Assessment in the Field of Pharmacovigilance (PRAC) recommends revocation of the approvals , press release of the BfArM of February 12, 2016, accessed on the same day.
↑ PRAC recommends that fusafungine nose and mouth sprays are no longer marketed , recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA dated February 12, 2016, accessed on the same day.
↑ Revocation of approvals, conclusion of Article 31 procedure , accessed on July 26, 2016.

[1] HPT Ammon (Ed.): Hunnius Pharmaceutical Dictionary . 9th edition. Walter de Gruyter, Berlin a. New York 2004, p. 617.

[2] European Committee for Risk Assessment in the Field of Pharmacovigilance (PRAC) recommends revocation of the approvals , press release of the BfArM of February 12, 2016, accessed on the same day.

[3] PRAC recommends that fusafungine nose and mouth sprays are no longer marketed , recommendation of the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA dated February 12, 2016, accessed on the same day.

[4] Revocation of approvals, conclusion of Article 31 procedure , accessed on July 26, 2016.